Repligen Corporation (RGEN) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$125.71
Price Target
$168.00
Target Range
$145.00 — $200.00
Analyst Rating
Buy
Forward P/E63.9x
Trailing P/E146.2x
Forward PEG—
Implied Growth+128.8%
Median Target$160.00
Analyst Spread32.7%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$145
+15.3%
Consensus
$168
+33.6%
Bull Case
$200
+59.1%
RGEN Price Target Analysis
Updated May 6, 2026As of May 6, 2026, Repligen Corporation (RGEN) has a Wall Street consensus price target of $168.00, based on estimates from 23 covering analysts. With the stock currently trading at $125.71, this represents a potential upside of +33.6%. The company has a market capitalization of $7.09B.
Analyst price targets range from a low of $145.00 to a high of $200.00, representing a 33% spread in expectations. The median target of $160.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 20 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, RGEN trades at a trailing P/E of 146.2x and forward P/E of 63.9x. Analysts expect EPS to grow +128.8% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+41.9%
Avg Forward P/E24.2x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 FTREFortrea Holdings Inc. | $1.4B | $14.53 | $18.83 | +29.6% | Hold | 21.5x | 12 |
 NTRANatera, Inc. | $28.4B | $206.77 | $262.50 | +27.0% | Buy | — | 27 |
 AZTAAzenta, Inc. | $1.1B | $24.61 | $44.67 | +81.5% | Buy | 31.4x | 12 |
 BRKRBruker Corporation | $5.8B | $38.01 | $52.13 | +37.1% | Buy | 18.0x | 32 |
 NVCRNovoCure Limited | $1.8B | $15.88 | $33.50 | +111.0% | Buy | — | 15 |
 ACADACADIA Pharmaceuticals Inc. | $3.8B | $22.35 | $34.78 | +55.6% | Buy | 50.4x | 37 |
 CRLCharles River Laboratories International, Inc. | $9.1B | $185.39 | $205.43 | +10.8% | Buy | 16.7x | 36 |
 ICLRICON Public Limited Company | $9.3B | $121.32 | $149.63 | +23.3% | Buy | 10.2x | 30 |
 RVTYRevvity, Inc. | $10.3B | $92.30 | $111.86 | +21.2% | Buy | 17.1x | 29 |
 TECHBio-Techne Corporation | $8.8B | $56.68 | $69.33 | +22.3% | Buy | 28.6x | 25 |
Upside Potential Comparison
NVCRAZTAACADBRKRFTRENTRAICLRTECHSee RGEN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RGEN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RGEN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRGEN — Frequently Asked Questions
Quick answers to the most common questions about buying RGEN stock.
What is the RGEN stock price target for 2026?
The consensus Wall Street price target for RGEN is $168, representing 33.6% upside from the current price of $125.71. With 23 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is RGEN a buy, sell, or hold?
RGEN has a consensus rating of "Buy" based on 23 Wall Street analysts. The rating breakdown is predominantly bullish, with 20 Buy/Strong Buy ratings. The consensus 12-month price target of $168 implies 33.6% upside from current levels.
Is RGEN stock overvalued or undervalued?
At a forward P/E of 63.89x, RGEN trades at a premium valuation. The consensus price target of $168 (33.6% upside) suggests analysts still see growth justifying the multiple.
How high can RGEN stock go?
The most bullish Wall Street analyst has a price target of $200 for RGEN, while the most conservative target is $145. The consensus of $168 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover RGEN stock?
RGEN is well covered by analysts, with 23 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 19 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the RGEN stock forecast?
The 12-month RGEN stock forecast based on 23 Wall Street analysts shows a consensus price target of $168, with estimates ranging from $145 (bear case) to $200 (bull case). The median consensus rating is "Buy".
What is RGEN's forward P/E ratio?
RGEN trades at a forward P/E ratio of 63.9x based on next-twelve-months earnings estimates compared to a trailing P/E of 146.2x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy RGEN stock?
Wall Street analysts are very optimistic on RGEN, with a "Buy" consensus rating and $168 price target (33.6% upside). 20 of 23 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do RGEN price targets vary so much?
RGEN analyst price targets range from $145 to $200, a 33% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $168 consensus represents the middle ground.